Curated news and analysis on clinical trials, drug approvals, and medical research.
Three new market reports project significant expansion in pharmaceutical R&D outsourcing, the U.S. pharmaceutical market, and biotechnology services outsourcing, driven by innovation, aging populations, and cost efficiency needs through 2035.
Health and Human Services Secretary Robert F. Kennedy Jr. announced plans to review the safety of ultra-processed foods, criticizing the GRAS exemption that allows companies to verify ingredient safety without FDA oversight since 1997.
Orphan drug development faces structural uncertainty due to small patient populations and varying global definitions, with regulators balancing early access against evidence requirements through accelerated pathways and post-market monitoring.
Edgewise Therapeutics and IDEAYA Biosciences released annual financial reports detailing clinical trial progress and strategic initiatives. Both companies are advancing multiple clinical-stage programs while managing significant operating expenses.
The FDA has proposed a new "plausible mechanism" pathway to approve customized treatments for rare diseases after testing in only a handful of patients, aiming to remove barriers for gene editing and other bespoke therapies that don't fit traditional approval systems.
Nautilus Biotechnology reported Q4 2025 financial results with operating expenses of $15.4 million, down 23% year-over-year. The company launched its Iterative Mapping Early Access Program in January 2026 and expects full commercial availability in late 2026.
Research initiatives are identifying novel therapeutic targets for Alzheimer's disease beyond traditional approaches, with focus on TREM2 agonists, metabolic interventions, and multi-omic data integration to diversify treatment strategies.
Eli Lilly's oral GLP-1 drug orforglipron demonstrated 6-8% weight loss in type 2 diabetes patients compared to 4-5% with oral semaglutide in a phase 3 trial, though discontinuation rates were higher due to gastrointestinal side effects.
New analysis suggests leptin hormone could normalize blood sugar in type 1 diabetes by acting on the brain, potentially offering an alternative to daily insulin injections based on research dating back to 2011.
Recent research shows younger heart disease patients face unique parenting challenges, middle-aged healthy eating protects against cognitive decline, and timing evening meals three hours before bed improves cardiovascular markers.
The global combination antibody therapy market is projected to grow from USD 268.17 billion in 2026 to USD 700.59 billion by 2035 at 11.26% CAGR, driven by rising cancer prevalence and multi-target treatment strategies.
Northwestern Medicine researchers identified a potent immunotherapy approach targeting the STING pathway for meningiomas, the most common primary brain tumor. The experimental drug STING agonist 8803 triggered tumor cell death and immune responses in human samples and mouse models.
The global biotechnology market is undergoing a transformation from discovery-based science to precision engineering, driven by AI, synthetic biology, and gene editing technologies, with projected growth of 13-15% over the next five years.
Researchers have developed a remote-controlled CAR T-cell therapy that can be switched off on demand using venetoclax, while new engineering strategies aim to overcome barriers in treating glioblastoma and other solid tumors.
Four biotech companies went public in one week raising nearly $1 billion, signaling a potential thaw in IPO markets after years of quiet activity. Regional life sciences hubs outside Boston and San Francisco are attracting record venture funding, while regulatory uncertainty at FDA continues to concern industry leaders.
Zydus Lifesciences plans to launch Semaglutide injection in India after patent expiry and introduced ANYRA, India's first indigenous Aflibercept biosimilar. The USFDA cleared the company's Ahmedabad injectable facility with zero observations.
NASA postponed the Artemis II lunar flyby mission to April after discovering a helium flow problem in the rocket's upper stage, forcing the Space Launch System back to its hangar for repairs just one day after announcing a March 6 launch date.
AstraZeneca's CALQUENCE received FDA approval as the first all-oral, fixed-duration regimen for chronic lymphocytic leukemia, while the EMA validated the marketing authorization application for ENHERTU in HER2-positive breast cancer treatment.
Semaglutide and tirzepatide represent distinct GLP-1-based weight management medications with different mechanisms of action. Clinical trials show varying weight loss outcomes, while new combination therapies undergo head-to-head testing.
Daily aspirin use does not prevent bowel cancer in the general population within 5-15 years and carries immediate bleeding risks, according to a new Cochrane review. However, long-term low-dose aspirin is associated with lower colorectal cancer risk in IBD patients.
